Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma.

ABSTRACT:

Rationale

Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of patients. In this study, we aimed to identify novel mechanism(s) responsible for bevacizumab-resistance in CD146-positive glioblastoma.

Methods

The study was performed using sera from GBM patients and human GBM cell lines in culture or xenografted in nude mice.

Results

We found that an increase in sCD146 concentration in sera of GBM patients after the first cycle of bevacizumab treatment was significantly associated with poor progression free survival and shorter overall survival.

SUBMITTER: Joshkon A 

PROVIDER: S-EPMC9590138 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature